References Alami N, Paterson J, Belanger S, Juste S, Grieshaber CK, Leyland-Jones B (2007) Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay. J Chemother 19:546–553PubMed Augustin E, Plocka E, Konopa J (2004) Induction of cell death (apoptosis) by antitumor triazoloacridinones in tumor cells. Drug Metab Rev 32(suppl. 1):33 Augustin E, Mos-Rompa
A, Skwarska A, Witkowski JM, Konopa J (2006) Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72:1668–1679PubMedCrossRef Berger B, Marguardt H, Westendorf J (1996) Pharmacological and toxicological aspects of new imidazoacridinone antitumor A-769662 price agents. Cancer Res selleck products 56:2094–2104PubMed
Bram EE, Ifergan I, Grimberg M, Lemke K, Składanowski A, Assaraf YG (2007) C421 allele-specific ABCG2 gene amplification www.selleckchem.com/products/Roscovitine.html confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol 74:41–53PubMedCrossRef Burger AM, Double JA, Konopa J, Bibby MC (1996) Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74:1369–1374PubMedCrossRef Burger AM, Jenkins TC, Double JA, Bibby MC (1999) Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81:367–375PubMedCrossRef Calabrese CR, Bibby MC, Double JA, Loadman PM (1998) Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemother Pharmacol 42:379–385PubMedCrossRef Calabrese CR, Loadman PM, Lim LS, Bibby MC, Double JA, Brown JE, Lamb JH (1999) In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos 27:240–245PubMed Cholody WM, Martelli S, Konopa J (1990) 8-substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones
as potential antineoplastic agents. J Med Chem 33:2852–2856PubMedCrossRef Cholody selleck kinase inhibitor WM, Martelli S, Konopa J (1992) Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 35:378–382PubMedCrossRef Cholody WM, Horowska B, Paradziej-Łukowicz J, Martelli S, Konopa J (1996) Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity against murine leukemias. J Med Chem 39:1028–1032PubMedCrossRef De Marco C, Zaffaroni N, Comijn E, Tesei A, Zoli W, Peters GJ (2007) Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.